174 related articles for article (PubMed ID: 17413631)
1. Composite lymphoma of the orbit treated with rituximab.
Kang SJ; Schmack I; Wojno TH; Grossniklaus HE
Ophthalmic Plast Reconstr Surg; 2007; 23(2):143-4. PubMed ID: 17413631
[TBL] [Abstract][Full Text] [Related]
2. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
4. Orbital richter syndrome.
Kiratli H; Tarlan B; Uzun S; Tanas Ö; Uner A
Orbit; 2013 Dec; 32(6):381-3. PubMed ID: 23895640
[TBL] [Abstract][Full Text] [Related]
5. Bilateral infiltrative disease of the extraocular muscles: a rare clinical presentation of early stage chronic lymphocytic leukemia.
Ramkissoon YD; Lee RW; Malik R; Hsuan JD; Potts MJ
Orbit; 2008; 27(4):293-5. PubMed ID: 18716967
[TBL] [Abstract][Full Text] [Related]
6. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
Perz J; Topaly J; Fruehauf S; Hensel M; Ho AD
Leuk Lymphoma; 2002 Jan; 43(1):149-51. PubMed ID: 11908720
[TBL] [Abstract][Full Text] [Related]
7. [Therapy-resistant cutaneous infiltrates in chronic lymphocytic leukemia].
Sucker C; Lorenz G; Dölken G; Stockschläder M
Hautarzt; 2006 Nov; 57(11):1009-12. PubMed ID: 16425068
[TBL] [Abstract][Full Text] [Related]
8. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
[TBL] [Abstract][Full Text] [Related]
10. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
Huh YO; Keating MJ; Saffer HL; Jilani I; Lerner S; Albitar M
Am J Clin Pathol; 2001 Sep; 116(3):437-43. PubMed ID: 11554173
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Hagemeister F
Drugs; 2010 Feb; 70(3):261-72. PubMed ID: 20166765
[TBL] [Abstract][Full Text] [Related]
13. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
14. Prolonging remission with rituximab maintenance therapy.
Hainsworth JD
Semin Oncol; 2004 Feb; 31(1 Suppl 2):17-21. PubMed ID: 15042530
[TBL] [Abstract][Full Text] [Related]
15. Composite Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia and Follicular Lymphoma: A Clinicopathological Study of Six Cases.
Jelloul FZ; Chen QH; Yang T; Haghi N; Brody J; Zhang X; Sheikh-Fayyaz S
Int J Surg Pathol; 2018 Apr; 26(2):135-144. PubMed ID: 29069998
[TBL] [Abstract][Full Text] [Related]
16. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody treatment of orbital lymphoma.
Sullivan TJ; Grimes D; Bunce I
Ophthalmic Plast Reconstr Surg; 2004 Mar; 20(2):103-6. PubMed ID: 15083076
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).
Sokol L; Agosti SJ
Am J Hematol; 2004 Feb; 75(2):107-9. PubMed ID: 14755378
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
Shimada K; Tomita A; Saito S; Kiyoi H
Br J Haematol; 2014 Aug; 166(3):455-7. PubMed ID: 24673649
[No Abstract] [Full Text] [Related]
20. [Renal infiltrate by a plasmocytoïd chronic B lymphocytic leukaemia and renal failure: a rare occurrence in nephropathology. A case report and review of the literature].
Aymard B; Beghoura R; Molina TJ
Nephrol Ther; 2011 Nov; 7(6):479-87. PubMed ID: 21439927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]